Sio Gene Therapies Inc. Common Stock
Compare this stock
SIOX Stock Report Card
$
37%
Performance
Score:
10/100
SIOX returned -58.25% in the last 12 months. Based on the other stocks in it's sector, it's performance is below average giving it a grade of 10 of 100.
Forecast
Score:
82/100
The 38 analysts offering 12-month price forecasts for SIOX have an average target of 0, with a high estimate of 0 and a low estimate of 0 giving it a grade of 82 of 100.
Technicals
Score:
86/100
Based on a multitude of SIOX's technicals indicators, it receives a grade of 85 of 100.
Volatility
Score:
10/100
SIOX had a -3,007.89% lower max drawdown compared to SPY over the last 12 months giving it a grade of 10 of 100.
Dividend
Score:
10/100
SIOX does not have a dividend payout ratio.
Profit
Score:
10/100
Could not get data for SIOX.
Sio Gene Therapies Inc. Common Stock Summary
Nasdaq / SIOX
Healthcare
Biotechnology
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
SIOX scored poorly on our reportcard. Here are some similar companies and how they performed.
